Who
Abizer Gaslightwala
CEO
Company insider
Files Form 4 as: CEO, Akari Therapeutics.
In numbers
- Trades disclosed
- 34
- Buys
- 7
- Sells
- 0
- Bought
- $57K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 26 Dec 2024
- Last trade
- 14 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
1 Jun 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Oct 2026filed 16 Oct 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code M | $819,333 at $0.0004 | filing |
| 14 Oct 2026filed 16 Oct 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code M | $37,733 at $0.0004 | filing |
| 14 Oct 2026filed 16 Oct 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | $312K19,333 at $16.16 | filing |
| 14 Oct 2026filed 16 Oct 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | $125K7,733 at $16.16 | filing |
| 29 Sep 2026filed 1 Oct 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $62K6,430 at $9.72 | filing |
| 18 Aug 2026filed 16 Oct 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —174,000 at $0.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,500 at $0.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,563 at $0.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,500 at $0.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,563 at $0.00 | filing |
| 16 Dec 2025filed 18 Dec 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —309,328 | filing |
| 16 Dec 2025filed 18 Dec 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $124K309,328 at $0.40 | filing |
| 16 Dec 2025filed 18 Dec 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —773,323 | filing |
| 16 Dec 2025filed 18 Dec 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $309K773,323 at $0.40 | filing |
| 25 Aug 2025filed 29 Aug 2025 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,7003,000 at $0.90 | filing |
| 22 Aug 2025filed 29 Aug 2025 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Bought | $7,4408,000 at $0.93 | filing |
| 21 Aug 2025filed 29 Aug 2025 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Bought | $9,40010,000 at $0.94 | filing |
| 24 Jun 2025filed 25 Jun 2025 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Bought | $6,0355,203 at $1.16 | filing |
| 23 Jun 2025filed 25 Jun 2025 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Bought | $1,084943 at $1.15 | filing |
| 20 Jun 2025filed 24 Jun 2025 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Bought | $12K10,000 at $1.20 | filing |
News
No headline names them, or the companies they trade most, lately.